Free Trial
CVE:AQS

Aequus Pharmaceuticals 11/29/2023 Earnings Report

Aequus Pharmaceuticals logo
C$0.0050 0.00 (-37.50%)
As of 04/25/2025

Aequus Pharmaceuticals EPS Results

Actual EPS
-C$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Aequus Pharmaceuticals Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aequus Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Aequus Pharmaceuticals Earnings Headlines

Aequus Pharmaceuticals Reports Revenue Growth Amid Restructuring
$19 for a FULL YEAR of stock picks?!
Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. Discover how a $100 investment could give you exposure to Musk's private AI project — via one overlooked stock.
Aequus Pharmaceuticals Inc. (AQSZF)
Aequus Pharmaceuticals Inc (AQS)
See More Aequus Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aequus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aequus Pharmaceuticals and other key companies, straight to your email.

About Aequus Pharmaceuticals

Aequus Pharmaceuticals (CVE:AQS) operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.

View Aequus Pharmaceuticals Profile

More Earnings Resources from MarketBeat